Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum CECT30292
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum CECT30292 is a specific probiotic bacterial strain belonging to the species *Lactobacillus plantarum* (recently reclassified as *Lactiplantibacillus plantarum*). It is primarily utilized as a key component of the multi-strain probiotic formulation AB21, which also includes *L. plantarum* CECT 7484, *L. plantarum* CECT 7485, and *Pediococcus acidilactici* CECT 7483. This strain and its associated combination have been clinically investigated for their ability to modulate the gut-lung axis and enhance systemic immune responses. Specifically, randomized controlled trials have evaluated its efficacy in reducing viral load, symptom duration, and the risk of severe disease progression in adults with mild COVID-19. It holds Qualified Presumption of Safety (QPS) status from the European Food Safety Authority (EFSA) and is typically marketed as a dietary supplement or nutraceutical.
- Other names
- Lactobacillus plantarum CECT 30292L. plantarum CECT 30292Lactiplantibacillus plantarum CECT 30292
Beyond the preview
Go deeper on lactobacillus plantarum CECT30292.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum CECT30292.